A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients

References

• Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006; 12: 1157–67
   PubMed Web of Science ®Google Scholar
• Silvestrini R, Daidone MG, Benini E, Faranda A, Tomasic G, Boracchi P, et al. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res 1996; 2: 2007–13
   PubMed Web of Science ®Google Scholar
• Petitjean A, Achatz MI, Børresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157–65
   PubMed Web of Science ®Google Scholar
• Soussi T. p53 alterations in human cancer: More questions than answers. Oncogene 2007; 26: 2145–56
   PubMed Web of Science ®Google Scholar
• Offersen, BV, Alsner, J, Olsen, KE, Riisbro, R, Brünner, N, Sørensen, FB, et al. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol 2008;47:618–32.
   PubMed Web of Science ®Google Scholar
• Offersen BV, Sørensen FB, Yilmaz M, Knoop A, Overgaard J. Chalkley estimates of angiogenesis in early breast cancer–relevance to prognosis. Acta Oncol 2002; 41: 695–703
   PubMed Web of Science ®Google Scholar
• Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353: 1641–8
   PubMed Web of Science ®Google Scholar
• Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949–55
   PubMed Web of Science ®Google Scholar
• Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007; 82: 247–53
   PubMed Web of Science ®Google Scholar
• Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006; 24: 2268–75
   PubMed Web of Science ®Google Scholar
• Hansen LL, Andersen J, Overgaard J, Kruse TA. Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement. APMIS 1998; 106: 371–7
   PubMed Web of Science ®Google Scholar
• Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 2000; 6: 3923–31
   PubMed Web of Science ®Google Scholar
• Kyndi, M, Sørensen, FB, Knudsen, H, Overgaard, M, Nielsen, HM, Andersen, J, et al. Tissue microarrays compared with whole sections and biochemical analyses: A subgroup analysis of DBCG82 b&c. Acta Oncol 2008;47:591–99.
   PubMed Web of Science ®Google Scholar
• Kyndi, M, Sørensen, FB, Knudsen, H, Alsner, J, Overgaard, M, Nielsen, HM, et al. Impact of BCL2 and p53 on post-mastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c. Acta Oncol 2008;47:608–17.
   PubMed Web of Science ®Google Scholar
• Soussi T, Wiman KG. Shaping genetic alterations in human cancer: The p53 mutation paradigm. Cancer Cell 2007; 12: 303–12
   PubMed Web of Science ®Google Scholar
• Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR. Problems with p53 immunohistochemical staining: The effect of fixation and variation in the methods of evaluation. Br J Cancer 1994; 69: 26–31
   PubMed Web of Science ®Google Scholar
• Battifora H. p53 immunohistochemistry: A word of caution. Hum Pathol 1994; 25: 435–7
   PubMed Web of Science ®Google Scholar
• Sjögren S, Inganäs M, Norberg T, Lindgren A, Nordgren H, Holmberg L, et al. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 173–82
   PubMed Web of Science ®Google Scholar